Abbott Laboratories 1Q profit surges 35 pct on global sales

advertisement

CHICAGO — Pharmaceutical company Abbott Laboratories Inc. said Wednesday that its first-quarter earnings surged 35 percent, driven by robust international sales of its rheumatoid arthritis medication Humira.

For the quarter ending March 31, the suburban Chicago company said its earnings rose to $937.9 million, or 60 cents per share. That's up from $697.5 million, or 45 cents, during the same period last year.

Excluding special items, earnings totaled $987.7 million, or 63 cents per share, just beating Wall Street forecasts.

Revenue jumped 14 percent to $6.77 billion, up from $5.95 billion last year.

Analysts polled by Thomson Financial forecast profit of 62 cents per share on revenue of $6.53 billion. Those estimates typically exclude one-time items.

"We had a strong first quarter delivering double-digit sales and earnings growth ahead of our expectations," said Thomas C. Freyman, Abbott's chief financial officer.

Much of the company's success was driven by sales of the company's blockbuster drug Humira, which grew nearly 54 percent worldwide to $878 million during the first-quarter.

The medication, which also treats other autoimmune diseases, is used in dozens of countries and was approved Wednesday for use in Japan.

Cowen & Co. analyst Sara Michelmore told investors that Abbott's first quarter was "very solid."

"Humira represents the primary growth and profitability driver for the company," she wrote in a research note Wednesday.

North Chicago-based Abbott reaffirmed its 2008 earnings guidance of $3.20 to $3.25 per share. Abbott expects second-quarter profit between 78 cents and 80 cents per share.

Analysts forecast 2008 earnings of $3.22 per share and second-quarter profit of 79 cents per share.

Abbott shares climbed 6 cents to $51.85 in early trading.

___

On the Net:

http://www.abbott.com

  • 0 Votes
  • Enjoy this article? Help vote it up the 'Vine.

Back To Top

Published to:

{"canLink":false,"threadId":0,"isPrivate":false}
Leave a Comment:
You're in Easy Mode. If you prefer, you can use XHTML Mode instead.
As a new user, you may notice a few temporary content restrictions. Click here for more info.
{"threadId":0,"contentId":"1434115"}
Start TrackingStart Tracking
Stop TrackingStop Tracking